Fidelity Advisor Biotechnology Fund (FBTIX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fidelity Advisor Biotechnology Fund (FBTIX) trades at $55.70. Fidelity Advisor Biotechnology Fund (FBTIX) is a non-diversified fund focused on biotechnology companies. Market cap: $2.40B, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for FBTIX: FBTIX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FBTIX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on FBTIX.
How is this calculated? →Fidelity Advisor Biotechnology Fund (FBTIX) Financial Services Profile
Fidelity Advisor Biotechnology Fund (FBTIX) is a $1.55 billion non-diversified fund specializing in biotechnology investments. The fund targets companies engaged in biotechnological research, development, manufacturing, and distribution, both domestically and internationally. It employs fundamental analysis to identify promising opportunities within the biotechnology sector, offering investors exposure to this specialized market.
What Is the Investment Thesis for FBTIX?
Fidelity Advisor Biotechnology Fund (FBTIX) presents an investment opportunity for those seeking exposure to the biotechnology sector. With a market capitalization of $2.40B, the fund focuses on companies involved in biotechnological research, development, and manufacturing. The fund's non-diversified nature allows for concentrated investments in promising companies, potentially leading to higher returns. Growth catalysts include advancements in biotechnology, regulatory approvals for new drugs, and increasing healthcare spending. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. The fund's beta of 0.90 suggests it is slightly less volatile than the overall market.
Based on FMP financials and quantitative analysis
FBTIX Key Highlights
Market capitalization of $2.40B indicates a significant presence in the biotechnology investment landscape.
- Non-diversified investment approach allows for concentrated positions in high-potential biotechnology companies.
- Focus on companies involved in biotechnological research, development, manufacture, and distribution provides targeted exposure to the sector.
- Investment in both domestic and foreign issuers offers diversification across geographies.
- Fundamental analysis-driven investment process aims to identify companies with strong financial conditions and industry positions.
Who Are FBTIX's Competitors?
FBTIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FCHKX Fidelity Advisor China Region Fund Class C | $67.55 | +0.25% | $2.88B | 47 |
| FDVIX Fidelity Advisor Diversified International Fund | $32.41 | -0.18% | $1.86B | 44 |
| FHKIX Fidelity China Region Fund | $71.72 | +0.25% | $2.88B | 47 |
| FIUIX Fidelity Utilities Fund | $33.49 | -0.83% | $1.38B | 50 |
| FMSTX Federated Hermes MDT Large Cap Value Fund | $42.69 | +0.66% | $1.98B | 47 |
| GCMG GCM Grosvenor Inc. | $13.47 | -2.25% | $2.52B | 95 |
| FSENX Fidelity Select Portfolios - Energy Portfolio | $92.48 | +0.37% | $2.66B | 69 |
| APAM Artisan Partners Asset Management Inc. | $42.05 | -1.06% | $2.99B | 70 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FBTIX's Key Strengths?
Strong focus on the high-growth biotechnology sector.
- Experienced investment team with deep industry knowledge.
- Access to Fidelity's extensive research resources.
- Non-diversified approach allows for concentrated investments.
What Are FBTIX's Weaknesses?
Non-diversified nature can lead to higher volatility.
- Performance is highly dependent on the success of biotechnology companies.
- Subject to regulatory risks and clinical trial failures.
- May underperform during periods of market downturn.
What Could Drive FBTIX Stock Higher?
Potential regulatory approvals for key drug candidates within the fund's portfolio.
- Continued advancements in biotechnology and personalized medicine driving innovation.
- Increasing healthcare spending globally supporting demand for new therapies.
What Are the Key Risks for FBTIX?
Clinical trial failures leading to significant losses in invested companies.
- Changes in government regulations impacting the biotechnology industry.
- Intense competition from other biotechnology companies.
- Market volatility and economic downturns affecting investor sentiment.
What Are the Growth Opportunities for FBTIX?
- Advancements in Genomics and Personalized Medicine: The increasing understanding of the human genome and the development of personalized medicine approaches present a significant growth opportunity for biotechnology companies. FBTIX can capitalize on this trend by investing in companies that are pioneering new genomic technologies and developing targeted therapies based on individual genetic profiles. The global market for personalized medicine is projected to reach $2.4 billion by 2028, offering substantial growth potential for companies in this space.
- Increasing Healthcare Spending: The rising global healthcare expenditure, driven by an aging population and increasing prevalence of chronic diseases, creates a favorable environment for biotechnology companies. FBTIX can benefit from this trend by investing in companies that are developing innovative therapies and diagnostics to address unmet medical needs.
- Regulatory Approvals for New Drugs: The approval of new drugs by regulatory agencies such as the FDA can be a major catalyst for biotechnology companies. FBTIX can capitalize on this by investing in companies that have promising drug candidates in late-stage clinical trials and are likely to receive regulatory approval. The FDA approved 50 new drugs in 2023, demonstrating the potential for significant value creation through regulatory approvals.
- Expansion into Emerging Markets: Emerging markets offer significant growth opportunities for biotechnology companies due to their large populations, increasing healthcare access, and rising disposable incomes. FBTIX can benefit from this trend by investing in companies that are expanding their operations into emerging markets and developing products specifically tailored to the needs of these markets. The pharmaceutical market in emerging economies is projected to grow at a rate of 8-10% per year, offering substantial growth potential.
- Strategic Partnerships and Acquisitions: Strategic partnerships and acquisitions can be a key growth driver for biotechnology companies, allowing them to expand their product portfolios, access new technologies, and enter new markets. FBTIX can capitalize on this trend by investing in companies that are actively pursuing strategic partnerships and acquisitions. The value of mergers and acquisitions in the biotechnology sector reached $100 billion in 2023, highlighting the importance of this growth strategy.
What Are FBTIX's Competitive Advantages?
- Established brand and reputation of Fidelity Investments.
- Experienced investment team with expertise in the biotechnology sector.
- Access to Fidelity's extensive research resources and network.
- Non-diversified approach allows for concentrated investments in high-potential companies.
What Does FBTIX Do?
Fidelity Advisor Biotechnology Fund (FBTIX) is a specialized investment vehicle within the Fidelity Investments family, focusing primarily on the biotechnology sector. The fund's strategy centers on identifying and investing in companies that are deeply involved in the research, development, manufacture, and distribution of biotechnological products, services, and processes. This includes firms that significantly benefit from scientific and technological advancements in the field of biotechnology. FBTIX invests in both domestic and foreign issuers, providing a global perspective on the biotechnology landscape. The fund employs a fundamental analysis approach, carefully evaluating factors such as each issuer's financial condition, industry position, and prevailing market and economic conditions to make informed investment decisions. As a non-diversified fund, FBTIX concentrates its investments in a smaller number of holdings compared to diversified funds, potentially leading to higher volatility but also the possibility of greater returns. The fund's investment decisions are driven by a team of experienced analysts who possess a deep understanding of the biotechnology industry and its dynamics. FBTIX aims to provide investors with exposure to the growth potential of the biotechnology sector, while also managing the inherent risks associated with this specialized area of the market.
What Products and Services Does FBTIX Offer?
- Invests primarily in common stocks of biotechnology companies.
- Focuses on companies involved in the research, development, manufacture, and distribution of biotechnological products.
- Targets companies benefiting from scientific and technological advances in biotechnology.
- Invests in both domestic and foreign issuers.
- Employs fundamental analysis to select investments.
- Operates as a non-diversified fund, concentrating investments in a smaller number of holdings.
How Does FBTIX Make Money?
- Generates revenue through management fees charged to investors.
- Fees are typically a percentage of the fund's assets under management (AUM).
- Investment performance can influence AUM and, consequently, management fee revenue.
What Industry Does FBTIX Operate In?
Fidelity Advisor Biotechnology Fund (FBTIX) operates within the asset management industry, specifically targeting the biotechnology sector. The biotechnology industry is characterized by rapid innovation, high growth potential, and significant regulatory oversight. The market is driven by increasing demand for novel therapies, advancements in genomics and personalized medicine, and an aging global population. Competition is intense, with numerous companies vying for market share. FBTIX differentiates itself through its focused investment strategy and fundamental analysis approach, aiming to identify companies with strong growth prospects and sustainable competitive advantages.
Who Are FBTIX's Key Customers?
- Individual investors seeking exposure to the biotechnology sector.
- Institutional investors, including pension funds, endowments, and foundations.
- Financial advisors and wealth managers seeking investment solutions for their clients.
FBTIX Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the fund's long-term potential, indicating that key stakeholders believe in its growth.
- Community sentiment has shifted positively, with discussions highlighting the fund's strong management and strategic investments in innovative biotech companies.
- The biotech sector has seen increased interest due to advancements in mRNA technology, positioning the fund to capitalize on emerging trends.
- Recent regulatory approvals for biotech products have sparked optimism, enhancing the fund's attractiveness to investors looking for growth opportunities.
Bear Case
- Concerns over high valuations in the biotech sector have led some investors to question the sustainability of price increases.
- Negative sentiment has emerged from discussions about potential regulatory hurdles that could impact the fund's portfolio companies.
- Recent market volatility has raised fears about the overall risk associated with biotech investments, leading to cautious sentiment among traders.
- Some community members express skepticism regarding the fund's ability to outperform broader market indices in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FBTIX Latest News
No recent news available for FBTIX.
FBTIX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FBTIX.
Price Targets
Wall Street price target analysis for FBTIX.
FBTIX MoonshotScore
What does this score mean?
The MoonshotScore rates FBTIX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Fidelity Advisor Biotechnology Fund Financial Services Stock: Key Questions Answered
What does Fidelity Advisor Biotechnology Fund do?
Fidelity Advisor Biotechnology Fund (FBTIX) is a non-diversified investment fund that focuses on companies involved in the biotechnology sector. The fund invests primarily in common stocks of companies engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes.
What are the main risks for FBTIX?
The main risks for Fidelity Advisor Biotechnology Fund (FBTIX) are inherent to the biotechnology sector. Clinical trial failures of key drug candidates within the fund's portfolio can significantly impact the fund's performance. Regulatory hurdles and changes in government policies can also pose risks to the biotechnology industry.
What are the key factors to evaluate for FBTIX?
Evaluate FBTIX on fundamentals, analyst consensus, and risk factors. Fidelity Advisor Biotechnology Fund (FBTIX) presents an investment opportunity for those seeking exposure to the biotechnology sector. Not financial advice.
How frequently does FBTIX data refresh on this page?
FBTIX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FBTIX's recent stock price performance?
Fidelity Advisor Biotechnology Fund (FBTIX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on the high-growth biotechnology sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FBTIX overvalued or undervalued right now?
Fidelity Advisor Biotechnology Fund (FBTIX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FBTIX before investing?
Before investing in Fidelity Advisor Biotechnology Fund (FBTIX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding FBTIX to a portfolio?
Key strength of Fidelity Advisor Biotechnology Fund (FBTIX): Strong focus on the high-growth biotechnology sector. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, limiting the depth of available insights.
- The biotechnology sector is inherently volatile and subject to rapid changes.